Loading...

BTMD - Haymaker Acquisition Corp. III

Analyst Coverage Initiated Signal for 06-24-2022
Analyst Coverage Initiated: BTMD rating Outperform by Cowen
Price Target: $11


Loading Chart BTMD

Stock Signal Information


Signal

Analyst Coverage Initiated: BTMD rating Outperform by Cowen
Price Target: $11
Report Date: 06-24-2022
Symbol: BTMD - Haymaker Acquisition Corp. III
Sector: Healthcare
Industry: Medical Care Facilities
Analyst Coverage Initiated: BTMD rating Outperform by Cowen
Price Target: $11

  BTMD Technical Analysis

Company Contact

Haymaker Acquisition Corp. III (BTMD)
501 Madison Avenue
New York, NY 75038
Phone: 212-616-9600
Website: https://biote.com
CEO:

BTMD, Haymaker Acquisition Corp. III

BTMD Haymaker Acquisition Corp. III Logo Image

NASDAQ, NASDAQ Global Market


Company Profile

biote Corp. operates in medical practice-building business within the hormone optimization space. The company trains practitioners how to identify and treat early indicators of hormone-related aging conditions. It also provides components to enable practitioners to establish, build, and operate a hormone optimization center to treat patients appropriate for therapy. The company was founded in 2011 and is headquartered in Irvine, Texas.